Multihance

(Gadobenate dimeglumine)

PreclinicalSmall molecule

BBracco Diagnostics, Inc

Multihance is one of 128 small molecule programs targeting Liver Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

127

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

TreatmentCompleted

Liver CancerPreclinical

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

TreatmentPreclinical

Completed

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

3 2

Alfenta

Jazz Pharmaceuticals

Preclinical

1 3

Niclocide

Bayer

Preclinical

1 4

Minipress

Pfizer

Preclinical

1 5

Emtriva

Gilead

Preclinical

1 6

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 7

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 8

Intuniv

PPromius Pharma, LLC

Preclinical

1 9

Sirturo

WWim Janssens

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalRecruiting

Study completion

NCT04373564

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Withdrawn·NNorthwestern University·Phase 2·NCT04910425

Multiple Sclerosis1 trial

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Terminated·UUniversity of Southern California·N/A·NCT02967380·14 enrolled

Coronary Artery Disease1 trial

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Completed·UUniversity of Utah·Phase 2·NCT01710254·30 enrolled

Magnetic Resonance Imaging (MRI)1 trial

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Completed·GGuerbet·Phase 2·NCT02633501·312 enrolled

CAR1 trial

QSM and Regional DCE MRI Permeability Using GOCART Technique

Withdrawn·UUniversity of Southern California··NCT03091803

9 more indications

Treatment1 trial

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

Completed·MM.D. Anderson Cancer Center·N/A·NCT04132843·6 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of MultiHance in Pediatric Patients

Terminated·BBracco Diagnostics, Inc·Phase 3·NCT00323310·92 enrolled

Contrast Agent1 trial

Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries

Completed·BBracco Diagnostics, Inc·Phase 3·NCT01260636·120 enrolled

Liver Cancer1 trial

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·N/A·NCT00539253·45 enrolled

Pediatric Patients1 trial

Retrospective Study of MRI in Pediatric Patients

Completed·BBracco Diagnostics, Inc··NCT02291822·90 enrolled

Breast Cancer1 trial

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT03703492·12 enrolled

Congenital Heart Disease1 trial

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

Completed·UUniversity of California, San Diego·Phase 3·NCT06406517·161 enrolled

Oligometastatic Disease1 trial

Evaluation of Liver Magnetic Resonance (MR) With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic Metastases

Terminated·UUniversity of Colorado, Denver·Approved·NCT04973007·10 enrolled

Unspecified1 trial

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting·GGuerbet·Phase 4·NCT04373564·2,076 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 23, 2004

MULTIHANCE MULTIPACK

NDA NDA021358

Nov 23, 2004

MULTIHANCE

NDA NDA021357

Nov 23, 2004

MULTIHANCE

NDA NDA021357

Nov 23, 2004

MULTIHANCE MULTIPACK

NDA NDA021358

May 8, 2007

MULTIHANCE

NDA NDA021357

May 8, 2007

MULTIHANCE MULTIPACK

NDA NDA021358

Sep 4, 2007

MULTIHANCE

NDA NDA021357

Sep 4, 2007

MULTIHANCE MULTIPACK

NDA NDA021358

Oct 2, 2009

MULTIHANCE

NDA NDA021357

Mar 17, 2010

MULTIHANCE

NDA NDA021357

Dec 20, 2010

MULTIHANCE

NDA NDA021357

Feb 16, 2011

MULTIHANCE MULTIPACK

NDA NDA021358

Sep 29, 2011

MULTIHANCE MULTIPACK

NDA NDA021358

Jul 6, 2012

MULTIHANCE

NDA NDA021357

Jul 6, 2012

MULTIHANCE MULTIPACK

NDA NDA021358

Jan 29, 2013

MULTIHANCE

NDA NDA021357

Jan 29, 2013

MULTIHANCE MULTIPACK

NDA NDA021358

Jul 30, 2013

MULTIHANCE MULTIPACK

NDA NDA021358

Jul 30, 2013

MULTIHANCE

NDA NDA021357

Sep 15, 2017

MULTIHANCE MULTIPACK

NDA NDA021358

Sep 15, 2017

MULTIHANCE

NDA NDA021357

Jan 19, 2018

MULTIHANCE

NDA NDA021357

Jan 19, 2018

MULTIHANCE MULTIPACK

NDA NDA021358

Apr 26, 2018

MULTIHANCE MULTIPACK

NDA NDA021358

Apr 26, 2018

MULTIHANCE MULTIPACK

NDA NDA021358

Apr 26, 2018

MULTIHANCE

NDA NDA021357

Apr 26, 2018

MULTIHANCE

NDA NDA021357

Nov 2, 2018

MULTIHANCE MULTIPACK

NDA NDA021358

Nov 2, 2018

MULTIHANCE

NDA NDA021357

Jan 26, 2024

MULTIHANCE

NDA NDA021357

Jan 26, 2024

MULTIHANCE MULTIPACK

NDA NDA021358

Jul 23, 2024

MULTIHANCE

NDA NDA021357

Jul 23, 2024

MULTIHANCE MULTIPACK

NDA NDA021358

Aug 14, 2024

MULTIHANCE

NDA NDA021357

Aug 14, 2024

MULTIHANCE MULTIPACK

NDA NDA021358

Mar 5, 2025

MULTIHANCE MULTIPACK

NDA NDA021358

Mar 5, 2025

MULTIHANCE

NDA NDA021357

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Gadobenate dimeglumine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadobenate dimeglumine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadobenate dimeglumine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021358). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBracco Diagnostics, Inc

Multihance

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Prostate Cancer1 trial

Multiple Sclerosis1 trial

Coronary Artery Disease1 trial

Magnetic Resonance Imaging (MRI)1 trial

CAR1 trial

Treatment1 trial

Safety and Efficacy1 trial

Contrast Agent1 trial

Liver Cancer1 trial

Pediatric Patients1 trial

Breast Cancer1 trial

Congenital Heart Disease1 trial

Oligometastatic Disease1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News